Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00212290 · ClinicalTrials.gov registry record · Phase 4
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
A Phase 4 study of Type 2 Diabetes Mellitus and Insulin Resistance, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
- 2
- Study locations
NCT00212290 is a Phase 4 study of Type 2 Diabetes Mellitus and Insulin Resistance that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 140 participants, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00212290, a Phase 4 study of Type 2 Diabetes Mellitus and Insulin Resistance, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to examine the effects of treating insulin resistance on memory and attention, brain glucose utilization, and proteins in spinal fluid.
Conditions Studied
Interventions
- DRUG placebo
- DRUG pioglitazone
- DRUG nateglinide
Study Locations (2)
Washington
- VA Puget Sound Health Care System (Seattle Campus) - Seattle
- VA Puget Sound Health Care System (American Lake Campus) - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2002-11 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00212290
The ClinicalTrials.gov registry entry for NCT00212290 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,747-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (95% lower). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00212290 reports 2 study locations spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00212290 about?
NCT00212290 is a clinical study titled "Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes". The purpose of this study is to examine the effects of treating insulin resistance on memory and attention, brain glucose utilization, and proteins in spinal fluid.
What is the current status of trial NCT00212290?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2002-11. Estimated completion is 2006-12.
What conditions does trial NCT00212290 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Insulin Resistance.
What interventions are being tested in trial NCT00212290?
The interventions under investigation include: placebo (DRUG), pioglitazone (DRUG), nateglinide (DRUG).
Who is sponsoring clinical trial NCT00212290?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00212290 being conducted?
This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
ACTIVE NOT RECRUITING · Phase 4
-
Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?
COMPLETED · Phase 4
-
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
COMPLETED · Phase 4
-
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
COMPLETED · Phase 4
-
Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes
COMPLETED · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.